science1 publisher
Rasonque's approval closed its compassionate-use program before insurers were ready to pay
Revolution Medicines' expanded access program for Rasonque closed immediately on FDA approval, leaving patients still mid-application to wait on insurers whose paperwork moves slower than metastatic pancreatic cancer.
Publishers:statnews.com
Reality
- Evidence62
- Adoption45
- Hype gap+12
- Incentives55